Moderna Inc (OQ:MRNA)

Business Focus: Biotechnology & Medical Research

Mar 27, 2024 06:30 am ET
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
CAMBRIDGE, MA / ACCESSWIRE / March 27, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced at its fifth Vaccines Day event clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline. The updates include data readouts in the Company's respiratory and latent and other vaccine portfolios, as well as commercial, manufacturing and financial announcements for its vaccines business.
Mar 26, 2024 07:00 am ET
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine.
Mar 22, 2024 09:31 am ET
Thinking about trading options or stock in NVIDIA, Alphabet, Microsoft, Moderna, or Vertiv Holdings?
NEW YORK, March 22, 2024 /PRNewswire/-- InvestorsObserver issues critical PriceWatch Alerts for NVDA, GOOGL, MSFT, MRNA, and VRT.
Feb 29, 2024 07:00 am ET
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
CAMBRIDGE, MA / ACCESSWIRE / February 29, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host its fifth annual Investor Event focused on vaccines and business updates on Wednesday, March 27, 2024. The presentation will begin at 9:00 a.m. ET.
Feb 28, 2024 07:00 am ET
Moderna to Present at Upcoming Investor Conferences in March 2024
CAMBRIDGE, MA / ACCESSWIRE / February 28, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:
Feb 22, 2024 06:30 am ET
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55
Feb 07, 2024 12:00 am ET
Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
CAMBRIDGE, MA / ACCESSWIRE / February 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Stéphane Bancel, Chief Executive Officer, has been elected to the National Academy of Engineering (NAE), broadly known as one of the highest acknowledgments of achievement in the field, in recognition of distinguished contributions to engineering and the "development and manufacturing of pharmaceutical products, including the COVID-19 vaccine."
Feb 01, 2024 07:00 am ET
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update.
Jan 31, 2024 05:45 pm ET
Moderna Named to Fortune's List of World's Most Admired Companies
CAMBRIDGE, MA / ACCESSWIRE / January 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been recognized on Fortune's World's Most Admired Companies list as part of its "All-Star" top-50 companies. This annual list is considered one of the leading measures of corporate reputation among global organizations.
Jan 08, 2024 07:00 am ET
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Company announces product sales for 2023 of approximately $6.7 billion (unaudited); U.S. COVID-19 market share season to date increased to 48% in 2023, up from 37% in 2022
Jan 04, 2024 08:31 am ET
Thinking about buying stock in ATIF Holdings, SoundHound AI, Halliburton, Moderna, or Co-Diagnostics?
NEW YORK, Jan. 4, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATIF, SOUN, HAL, MRNA, and CODX.
Jan 03, 2024 08:31 am ET
Thinking about trading options or stock in Agios Pharmaceuticals, Moderna, Vertex Pharmaceuticals, Applied Materials, or Hut 8?
NEW YORK, Jan. 3, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGIO, MRNA, VRTX, AMAT, and HUT.
Dec 20, 2023 04:05 pm ET
Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / December 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced that Jamey Mock, Chief Financial Officer, will present at the 42nd annual J.P. Morgan Healthcare Conference on Monday, January 8th at 6:45 p.m. ET / 3:45 p.m. PT.
Dec 14, 2023 06:00 pm ET
Dec 14, 2023 08:31 am ET
Thinking about trading options or stock in Moderna, Microsoft, General Electric, ASML Holding, or Seadrill?
NEW YORK, Dec. 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, MSFT, GE, ASML, and SDRL.
Dec 14, 2023 06:30 am ET
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patie
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis or death by 62% (HR=0.384 [95% CI, 0.172-0.858]; one-sided nominal p= 0.0077) compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection
Dec 14, 2023 06:00 am ET
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
First lead candidate to address a solid tumor indication with significant unmet medical need
Dec 12, 2023 08:00 am ET
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
CAMBRIDGE, MA / ACCESSWIRE / December 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- and long-term business goals.
Dec 11, 2023 06:45 am ET
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected No
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-002, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant treatment in patients with completely resected (R0) Stage II, IIIA or IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). Global recruitment of the INTerpath-002 has begun, and the first patients enrolled in Australia.
Dec 07, 2023 07:00 am ET
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
The Company's ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to employees and communities
Nov 21, 2023 05:00 am ET
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
Quotient's Somatic Genomics platform reveals new approaches to treat disease based on the vast genetic variation present in the body's trillions of cells
Nov 14, 2023 07:00 am ET
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
CAMBRIDGE, MA / ACCESSWIRE / November 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host its second virtual ESG investor event at 8:00 a.m. ET on Thursday, December 7, 2023.
Nov 08, 2023 04:15 pm ET
Moderna to Present at Upcoming Conferences in November 2023
CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
Nov 08, 2023 07:00 am ET
Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
The Company demonstrates how its integrated Artificial Intelligence ecosystem accelerates innovation at scale and creates value across the enterprise
Nov 07, 2023 08:00 am ET
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / November 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2024 Best Places to Work report for the third consecutive year.
Nov 02, 2023 06:30 am ET
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
CAMBRIDGE, MA / ACCESSWIRE / November 2, 2023 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2023.
Nov 01, 2023 10:30 am ET
Flagship Pioneering Launches Pioneering Intelligence
CAMBRIDGE, Mass., Nov. 1, 2023 /PRNewswire/ -- Flagship Pioneering today launched Pioneering Intelligence, an initiative of Flagship Pioneering harnessing artificial intelligence (AI) to accelerate innovation in the life sciences and beyond. Flagship marked the official launch of Pioneering Intelligence with an AI Summit that drew tech and life sciences leaders from around the globe for a day long series of talks. Initiated in 2021, Pioneering Intelligence will augment the capabilities of Flagship companies, drive AI and machine learning (ML) innovation, and originate new platform companies
Oct 30, 2023 03:00 am ET
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission
New partnership will harness Moderna's mRNA rapid-response platform, clinically validated during the COVID-19 pandemic, to accelerate epidemic and pandemic vaccine developmentFirst project will enable rapid pre-clinical testing of antigen designs for high-risk viral families, to advance global outbreak readiness
Oct 26, 2023 02:45 pm ET
Moderna Named a Top Employer by Science for Ninth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / October 26, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.
Oct 24, 2023 07:00 am ET
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
mRNA-1083 is Moderna's first respiratory combination vaccine candidate to enter a Phase 3 trial
Oct 24, 2023 06:30 am ET
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics
Partnership enables Moderna to leverage Caris' vast library of de-identified, multi-modal data and analytics capabilities to accelerate precision medicine and the delivery of novel medicines to patients
Oct 19, 2023 07:45 am ET
Moderna to Host Second Digital Investor Event on November 8th, 2023
CAMBRIDGE, MA / ACCESSWIRE / October 19, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a virtual Digital and AI Investor Event at 8:00 a.m. ET on Wednesday, November 8, 2023.
Oct 12, 2023 07:00 am ET
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update.
Oct 04, 2023 07:00 am ET
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines
Sep 29, 2023 07:37 pm ET
Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation
CAMBRIDGE, MA / ACCESSWIRE / September 29, 2023 / Moderna, Inc. (NASDAQ:MRNA) has become aware that TRC Capital Investment Corporation (TRC Capital) has amended its unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price that is now $99.00 per share, down from $107.56 per share under the original offer. TRC Capital's amended offer price of $99.00 per share is lower than the closing price of Moderna common stock on the Nasdaq Global Select Market on September 28, 2023, the last trading day prior to the announceme
Sep 14, 2023 10:15 am ET
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union
The positive opinion follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines for autumn/winter 2023 vaccination campaigns
Sep 13, 2023 06:30 am ET
Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers than Fluzone HD
Sep 11, 2023 01:53 pm ET
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Clinical data show robust immune responses across multiple circulating variants, including EG.5, FL.1.5.1, and BA.2.86Updated vaccine to be available in pharmacies and care settings across the U.S. in the coming days
Sep 11, 2023 07:00 am ET
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules
Sep 11, 2023 06:30 am ET
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
CAMBRIDGE, Mass., Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry.  She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corporate alliance strategy.
Sep 08, 2023 04:37 pm ET
Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
CAMBRIDGE, MA / ACCESSWIRE / September 8, 2023 / Moderna, Inc. (Nasdaq:MRNA) has been notified that TRC Capital Investment Corporation (TRC Capital) has made an unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price of $107.56 per share. TRC Capital's offer price of $107.56 per share is approximately 4.44% lower than the closing price of Moderna common stock on the Nasdaq Global Select Market on September 1, 2023, the last trading day prior to the date of the offer, September 5, 2023.
Sep 06, 2023 04:30 pm ET
Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / September 6, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in a fireside chat at Morgan Stanley's 21st Annual Global Healthcare Conference on Tuesday, September 12th at 12:15 p.m. ET.
Sep 06, 2023 07:00 am ET
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 vaccine for the fall 2023 season
Aug 30, 2023 07:00 am ET
Moderna to Host Investor Event - R&D Day and Business Updates
CAMBRIDGE, MA / ACCESSWIRE / August 30, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 1:00 p.m. ET on Wednesday, September 13, 2023.
Aug 17, 2023 04:15 pm ET
Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variant
Aug 03, 2023 06:30 am ET
Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62
Jul 27, 2023 09:31 am ET
Thinking about trading options or stock in Microsoft, Apple, NVIDIA, Moderna, or COMPASS Pathways?
NEW YORK, July 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MSFT, AAPL, NVDA, MRNA, and CMPS.
Jul 26, 2023 06:45 am ET
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma. Global recruitment in V940-001 has begun, and the first patients are now enrolling in Aus
Jul 13, 2023 07:00 am ET
Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
CAMBRIDGE, MA / ACCESSWIRE / July 13, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023 to report its second quarter 2023 financial results, and provide a corporate update.
Jul 05, 2023 07:00 am ET
Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
Moderna has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia
Jul 03, 2023 01:00 am ET
Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine
The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines
Jun 29, 2023 01:34 pm ET
MODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE
Health Canada submission follows international recommendations to develop monovalent XBB.1.5 COVID-19 vaccines
Jun 27, 2023 09:31 am ET
Thinking about trading options or stock in Tesla, Moderna, Taiwan Semiconductor Manufacturing, Amazon.com, or Meta Platforms?
NEW YORK, June 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, MRNA, TSMC, AMZN, and META.
Jun 22, 2023 04:05 pm ET
Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine
Preliminary clinical data demonstrated a robust immune response by the company's XBB.1.5 monovalent vaccine against XBB descendent lineage viruses
Jun 05, 2023 08:00 am ET
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Su
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone
Jun 01, 2023 04:05 pm ET
Moderna to Present at Upcoming Conferences in June 2023
CAMBRIDGE, MA / ACCESSWIRE / June 1, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:
May 30, 2023 08:00 am ET
May 19, 2023 07:00 am ET
Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
May 16, 2023 06:00 am ET
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit
May 04, 2023 01:01 pm ET
MODERNA AND NOVOCOL PHARMA ANNOUNCE FILL-FINISH AGREEMENT FOR CANADIAN-MADE MRNA VACCINES
Vaccines manufactured at Moderna's state-of-the-art Canadian mRNA facility to be prepared and packaged at Novocol's Ontario-based facility
May 04, 2023 06:30 am ET
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
CAMBRIDGE, MA / ACCESSWIRE / May 4, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the first quarter of 2023.
May 03, 2023 04:05 pm ET
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to determine a recommended dose
May 02, 2023 05:15 pm ET
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna's Enterprise Solutions Hubs in Warsaw, Poland, and Atlanta, U.S.
Apr 20, 2023 04:05 pm ET
Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
CAMBRIDGE, MA / ACCESSWIRE / April 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023 to report its first quarter 2023 financial results, and provide a corporate update.
Apr 20, 2023 07:30 am ET
Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
Moderna invests in developing quantum computing skills and exploring the use of quantum computing in developing future mRNA medicines
Apr 16, 2023 11:00 am ET
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Pa
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection
Apr 12, 2023 09:31 am ET
Thinking about trading options or stock in Exxon Mobil, Walt Disney, Alphabet, Costco, or Moderna?
NEW YORK, April 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XOM, DIS, GOOG, COST, and MRNA.
Apr 11, 2023 07:00 am ET
Moderna Announces Clinical and Program Updates at 4th Vaccines Day
Next-generation, refrigerator-stable COVID-19 vaccine candidate, mRNA-1283, has dosed first participant in its Phase 3 trial
Apr 06, 2023 05:00 pm ET
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Mar 31, 2023 09:31 am ET
Thinking about trading options or stock in Amazon, Costco, Apple, Pfizer, or Moderna?
NEW YORK, March 31, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMZN, COST, AAPL, PFE, and MRNA.
Mar 30, 2023 07:00 am ET
Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna's global public health commitments
Mar 24, 2023 07:30 am ET
Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
CAMBRIDGE, MA / ACCESSWIRE / March 24, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will present its Vaccines Day for analysts and investors at 8:00 a.m. ET on Tuesday, April 11, 2023.
Mar 23, 2023 07:02 am ET
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nanoparticle (ctLNP) delivery system
Mar 23, 2023 07:00 am ET
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent...
Mar 14, 2023 05:40 pm ET
Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting being held April 14-19 in Orlando, FL. mRNA-4157/V940 is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
Mar 10, 2023 11:00 am ET
Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
Expansion includes new West Coast offices in South San Francisco, California and Seattle, Washington
Feb 28, 2023 07:30 am ET
Moderna to Present at Cowen's 43rd Annual Health Care Conference
CAMBRIDGE, MA / ACCESSWIRE / February 28, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at Cowen's 43rd Annual Health Care Conference on Monday, March 6th at 9:10 a.m. ET.
Feb 23, 2023 08:36 am ET
Thinking about trading options or stock in NVIDIA, Moderna, Domino's Pizza, Apple, or Etsy?
NEW YORK, Feb. 23, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVDA, MRNA, DPZ, AAPL, and ETSY.
Feb 23, 2023 07:00 am ET
Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61
Feb 22, 2023 07:00 am ET
Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilities
Feb 17, 2023 11:00 am ET
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214
Feb 16, 2023 04:05 pm ET
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
mRNA-1010 demonstrated superiority on seroconversion rates for A/H3N2 and A/H1N1, superiority on geometric mean titer ratios for A/H3N2, and non-inferiority on geometric mean titer ratios for A/H1N1
Feb 03, 2023 08:45 am ET
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The platform, which was also utilized in the vaccine candidate’s P
Feb 02, 2023 07:00 am ET
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
CAMBRIDGE, MA / ACCESSWIRE / February 2, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023 to report its fourth quarter and full year 2022 financial results, and provide a corporate update.
Jan 30, 2023 07:15 am ET
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Jan 18, 2023 08:32 am ET
Thinking about trading options or stock in Moderna, United Airlines, Interactive Brokers, McDonald's, or Chevron?
NEW YORK, Jan. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, UAL, IBKR, MCD, and CVX.
Jan 17, 2023 04:05 pm ET
Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Jan 09, 2023 07:00 am ET
Moderna Announces Advances Across mRNA Pipeline and Provides Business Update
COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited)
Jan 05, 2023 04:05 pm ET
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a...
Jan 05, 2023 04:05 pm ET
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions
Jan 04, 2023 07:00 am ET
Moderna to Acquire OriCiro Genomics
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Jan 03, 2023 07:00 am ET
Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / January 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the 41st annual J.P. Morgan Healthcare Conference on Monday, January 9th at 5:15 p.m. ET.
Dec 21, 2022 07:05 pm ET
Moderna Finalizes Strategic Partnership with UK Government
Facility to enable access to domestically manufactured mRNA respiratory vaccines, pending regulatory assessment and licensure
Dec 20, 2022 07:42 am ET
Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial
Newly created role will have responsibility for commercial efforts in Europe, Middle East and Canada
Dec 19, 2022 08:31 am ET
Thinking about trading options or stock in Madrigal Pharmaceuticals, Amazon, Moderna, Apple, or Baidu?
NEW YORK, Dec. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MDGL, AMZN, MRNA, AAPL, and BIDU.
Dec 16, 2022 07:30 am ET
Dec 15, 2022 08:31 am ET
Thinking about trading options or stock in Ambarella, Apple, Jabil, Moderna, or Monster Beverage?
NEW YORK, Dec. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMBA, AAPL, JBL, MRNA, and MNST.
Dec 14, 2022 08:31 am ET
Thinking about trading options or stock in Block, Moderna, Apple, Activision Blizzard, or General Electric?
NEW YORK, Dec. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SQ, MRNA, AAPL, ATVI, and GE.
Dec 13, 2022 08:31 am ET
Thinking about trading options or stock in Moderna, Docusign, Trade Desk, Apple, or Oracle?
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, DOCU, TTD, AAPL, and ORCL.
Dec 13, 2022 07:00 am ET
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 T
mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection
Dec 07, 2022 04:05 pm ET
Brad Miller Joins Moderna as Chief Information Officer
Current Chief Digital Officer, Marcello Damiani, to retire in March
Nov 29, 2022 08:00 am ET
Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / November 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, Dec. 1st at 9:00 a.m. ET.
Nov 17, 2022 08:10 am ET
David Jiménez Joins Moderna As U.S. General Manager
CAMBRIDGE, MA / ACCESSWIRE / November 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of David Jiménez as General Manager, United States, effective November 21, 2022. Mr. Jiménez will be responsible for commercial efforts in the United States, reporting to Arpa Garay, Moderna's Chief Commercial Officer.
Nov 16, 2022 04:30 pm ET
Moderna Tops BioSpace's Best Places to Work Ranking for Second Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / November 16, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it was ranked the number one large employer in BioSpace's 2023 Best Places to Work in Biopharma report.
Nov 14, 2022 07:00 am ET
Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial
In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273
Nov 10, 2022 07:35 am ET
Moderna Shares Environmental, Social and Governance Highlights at First ESG Day
Moderna continues development of at least 15 vaccine programs targeting emerging or neglected infectious diseases by 2025 as part of global health program
Nov 09, 2022 08:00 am ET
Moderna to Present at the Jefferies 2022 London Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / November 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, Nov. 16th at 8:30 a.m. ET.
Nov 04, 2022 05:00 pm ET
Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster
mRNA-1273.222 targets BA.4/BA.5 Omicron subvariants and follows the approval of mRNA-1273.214 (SPIKEVAX Bivalent) in Canada, which targets the Omicron BA.1 subvariant
Nov 03, 2022 07:00 am ET
Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates
Third quarter 2022 revenues of $3.4 billion; GAAP net income of $1.0 billion and GAAP diluted EPS of $2.53
Nov 01, 2022 09:31 am ET
Thinking about trading options or stock in Tesla, Uber Technologies, Pinduoduo, Exxon Mobil, or Moderna?
NEW YORK, Nov. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, UBER, PDD, XOM, and MRNA.
Nov 01, 2022 01:30 am ET
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
CAMBRIDGE, MA / ACCESSWIRE / November 1, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omic
Oct 27, 2022 04:05 pm ET
Moderna to Host First Environmental, Social and Governance (ESG) Day on November 10, 2022
CAMBRIDGE, MA / ACCESSWIRE / October 27, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its first virtual ESG Day for analysts and investors at 9:00 a.m. ET on Thursday, November 10.
Oct 27, 2022 02:50 pm ET
Moderna Named a Top Employer by Science for Eighth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / October 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it was ranked one of the top employers in the global biopharmaceutical industry by Science and Science Careers' 2022 Top Employers Survey for the eighth consecutive year. Moderna was ranked no. 7 on the list this year and was recognized for its commitment to innovative leadership, respect for employees and corporate social responsibility.
Oct 21, 2022 09:32 am ET
Thinking about trading options or stock in Moderna, Bristol-Myers Squibb, Northrop Grumman, BioNTech, or Tesla?
NEW YORK, Oct. 21, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, BMY, NOC, BNTX, and TSLA.
Oct 19, 2022 01:00 pm ET
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
Positive recommendation follows the recent approval of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), a bivalent booster vaccine targeting the Omicron BA.1 subvariant, in September
Oct 19, 2022 12:30 pm ET
EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union
Announcement follows CHMP's previous decision to issue a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include children 6 years of age and older
Oct 17, 2022 06:00 am ET
Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries
Given the sufficient supply of COVID-19 vaccines globally, Moderna & Gavi have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022
Oct 13, 2022 08:00 am ET
Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022
CAMBRIDGE, MA / ACCESSWIRE / October 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 3, 2022 to report its third quarter 2022 financial results, and provide a corporate update.
Oct 12, 2022 09:31 am ET
Thinking about trading options or stock in Moderna, Micron, Tesla, Autozone, or Walt Disney?
NEW YORK, Oct. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNA, MU, TSLA, AZO, and DIS.
Oct 12, 2022 07:15 am ET
Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine
Companies on track to report data from the ongoing Phase 2 trial of mRNA-4157/V940 in combination with KEYTRUDA® as adjuvant therapy in high-risk melanoma in 4Q 2022
Oct 12, 2022 07:00 am ET
Moderna exercises option to license proprietary targeting technology from Autolus
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programed T cell therapies, today announces that Moderna (MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and...
Sep 29, 2022 08:00 am ET
Moderna Creates New Executive Committee Role Ahead of New Product Launches
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
Sep 28, 2022 04:50 am ET
European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine
Filing follows approval of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), a bivalent booster vaccine targeting the Omicron BA.1 subvariant, in SeptemberModerna's Omicron-targeting bivalent boosters now authorized in the United States, Australia, Canada, Europe, Japan, South Korea, Switzerland, Singapore, Taiwan, and the UK
Sep 20, 2022 10:34 am ET
Thinking about buying stock in Ford, CSX Corp, DXC Technology, Moderna, or Purple Innovation?
NEW YORK, Sept. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for F, CSX, DXC, MRNA, and PRPL.
Sep 14, 2022 10:46 am ET
Thinking about trading options or stock in Starbucks, Block, Moderna, Arch Resources, or CF Industries?
NEW YORK, Sept. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SBUX, SQ, MRNA, ARCH, and CF.
Sep 12, 2022 07:00 am ET
Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214
CAMBRIDGE, MA / ACCESSWIRE / September 12, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.214 (Spikevax Bivalent Original/Omicron BA.1). Spikevax Bivalent Original/Omicron contains mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant
Sep 08, 2022 07:00 am ET
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit
Sep 06, 2022 04:05 pm ET
Moderna to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / September 6, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Stephen Hoge, M.D., President, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13th at 10:00 a.m. ET.
Sep 01, 2022 11:00 am ET
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine
mRNA-1273.214 is the first Omicron-targeting bivalent COVID-19 booster vaccine approved in Canada
Sep 01, 2022 09:31 am ET
Thinking about trading options or stock in Microsoft, Block, Alibaba, Moderna, or Coca-Cola?
NEW YORK, Sept. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MSFT, SQ, BABA, MRNA, and KO.
Sep 01, 2022 09:00 am ET
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union
Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273
Aug 31, 2022 10:25 am ET
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
Moderna's Bivalent Booster Shots to be Available Nationwide In Coming DaysmRNA-1273.222 Targets BA.4/.5 Strains of Omicron Variant
Aug 30, 2022 01:00 am ET
Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia
Australia becomes among the first countries in the world to approve the use of a next-generation bivalent COVID-19 vaccine
Aug 29, 2022 07:00 am ET
Moderna to Host R&D Day on Thursday, September 8, 2022
CAMBRIDGE, MA / ACCESSWIRE / August 29, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host its in-person and virtual R&D Day at 9:00 a.m. ET on Thursday, September 8, 2022.
Aug 29, 2022 06:10 am ET
Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
Switzerland becomes among the first countries in the world to approve the use of a next-generation bivalent COVID-19 booster vaccine
Aug 26, 2022 08:00 am ET
Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty® unlawfully infringes patents Moderna filed between 2010 and 2016
Aug 22, 2022 07:00 am ET
Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada
Government of Canada exercises option to purchase an additional 4.5 million doses of Moderna's Omicron-containing bivalent vaccine booster candidates
Aug 17, 2022 08:00 am ET
James Mock Joins Moderna as Chief Financial Officer
CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Following the appointment of Mr. Mock, David Meline will retire as the Company's CFO effective the same date but will remain as a consultant to the Company to assist with the transition.
Aug 15, 2022 09:31 am ET
Thinking about trading options or stock in Nvidia, Moderna, Deere & Company, Apple, or Walmart?
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVDA, MRNA, DE, AAPL, and WMT.
Aug 15, 2022 07:00 am ET
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK
Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273
Aug 08, 2022 12:00 am ET
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses
Contractually remaining doses of Moderna's COVID-19 vaccine (Spikevax, mRNA-1273) will be converted to Moderna's next generation Omicron-containing bivalent vaccines
Aug 03, 2022 09:41 am ET
Thinking about trading options or stock in Tesla, Intellia Therapeutics, PayPal, Exxon Mobil, or Moderna?
NEW YORK, Aug. 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, NTLA, PYPL, XOM, and MRNA.
Aug 03, 2022 07:00 am ET
Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates
Second quarter 2022 revenues of $4.7 billion; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24
Jul 29, 2022 08:00 am ET
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Addi
New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses
Jul 22, 2022 08:00 am ET
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
CAMBRIDGE, MA / ACCESSWIRE / July 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the conditional marketing authorization (CMA) to include a booster dose of Spikevax, the Company's COVID-19 vaccine, at the 50 µg dose level for adolescents (12-17 years) at least three months after completion of the primary series.
Jul 18, 2022 11:00 pm ET
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years
Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Argentina, Canada, Israel, the US, and Taiwan for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6 months to five years
Jul 14, 2022 11:30 am ET
Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)
Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults
Jul 13, 2022 08:00 am ET
Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022
CAMBRIDGE, MA / ACCESSWIRE / July 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, August 3, 2022 to report its second quarter 2022 financial results, and provide a corporate update.
Jul 12, 2022 07:00 am ET
Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215
Moderna advances global health commitment with mRNA vaccine candidate against the Nipah virus, a lethal pathogen with pandemic potential
Jul 11, 2022 08:00 am ET
Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Author
mRNA-1273.214 has now demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants, ancestral virus, Alpha, Beta, Delta, and Gamma
Jun 22, 2022 07:03 am ET
Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5
mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study
Jun 21, 2022 07:05 pm ET
Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom
Manufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses
Jun 17, 2022 09:05 am ET
Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
mRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart
Jun 08, 2022 07:00 am ET
Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant
Jun 07, 2022 07:00 am ET
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter a Phase 3 trialmRNA-1010 is one of several influenza vaccine candidates being developed in Moderna's respiratory portfolioModerna now has four programs in Phase 3 studies: Omicron-containing bivalent COVID booster, influenza, RSV, CMV
Jun 02, 2022 06:30 am ET
Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement
CAMBRIDGE, MA / ACCESSWIRE / June 2, 2022 / Moderna, Inc.(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the European Commission (EC) to amend their originally agreed contractual delivery schedules for the Moderna COVID-19 vaccine booster product (Spikevax, mRNA-1273) or updated booster vaccine candidate.
Jun 01, 2022 07:57 am ET
Moderna to Present at Upcoming Conferences in June 2022
CAMBRIDGE, MA / ACCESSWIRE / June 1, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:
May 31, 2022 03:56 am ET
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda (
May 31, 2022 03:40 am ET
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1, 2022
May 24, 2022 08:30 am ET
Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)
Senti Biosciences, Inc. (“Senti Bio”), a leading gene circuit company, today announced that it has secured additional funding from Leaps by Bayer, the impact investment arm of Bayer AG, in the form of a Note Subscription Agreement for an unsecured,...
May 18, 2022 03:55 pm ET
Moderna to Present at the UBS 2022 Global Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24th at 9:15 a.m. ET.
May 18, 2022 07:00 am ET
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
May 17, 2022 07:00 am ET
Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
May 11, 2022 08:00 am ET
Departure of Jorge Gomez and Continuation of David Meline as Chief Financial Officer
CAMBRIDGE, MA / ACCESSWIRE / May 11, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the Company, effective immediately. The announcement follows the May 10 public disclosure by Mr. Gomez's former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting.
May 09, 2022 07:00 am ET
Moderna to Host Annual Science and Technology Day on May 17, 2022
CAMBRIDGE, MA / ACCESSWIRE / May 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that that it will host its in-person Science and Technology Day for analysts and investors at 9:00 a.m. ET on Tuesday, May 17 in Boston, MA.
May 04, 2022 09:31 am ET
Thinking about trading options or stock in Advanced Micro Devices, Moderna, Lumentum, Caesars Entertainment, or General Electric?
NEW YORK, May 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, MRNA, LITE, CZR, and GE.
May 04, 2022 06:52 am ET
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
First quarter 2022 revenues of $6.1 billion; GAAP net-income of $3.7 billion and GAAP diluted EPS of $8.58
Apr 29, 2022 10:05 am ET
Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Apr 28, 2022 07:10 am ET
Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age
Submission to Regulators Globally Is Based on Phase 2/3 Studies of mRNA-1273 in Young Children
Apr 27, 2022 08:55 am ET
Arpa Garay Joins Moderna as Chief Commercial Officer
CAMBRIDGE, MA / ACCESSWIRE / April 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Arpa Garay will join Moderna as Chief Commercial Officer, effective Monday, May 31, 2022. She will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel.
Apr 19, 2022 06:50 am ET
Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
Moderna's first bivalent booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron; superiority was maintained for six months after booster for the Beta and Omicron variants
Apr 13, 2022 08:00 am ET
Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022
CAMBRIDGE, MA / ACCESSWIRE / April 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 4, 2022 to report its first quarter 2022 financial results, and provide a corporate update.
Apr 11, 2022 09:00 am ET
Jorge Gomez Joins Moderna as Chief Financial Officer
CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join Moderna as Chief Financial Officer, effective Monday, May 9, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane Bancel.
Apr 11, 2022 08:00 am ET
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Apr 07, 2022 07:00 am ET
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
Apr 04, 2022 09:00 am ET
Moderna Launches New Charitable Foundation
Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19
Apr 01, 2022 09:31 am ET
Thinking about trading options or stock in Chevron, Tesla, Moderna, Walgreens Boots Alliance, or Micron Technology?
NEW YORK, April 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CVX, TSLA, MRNA, WBA, and MU.
Mar 31, 2022 09:00 am ET
Leaders: Moderna, Tilray, PharmaDrug, and Vinco; Visionary CEO Highlight New Trends in Vaccines, Biotech, Digital Media, and Consumer Brands
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Moderna, Inc. (NASDAQ: MRNA), PharmaDrug (OTC: LMLLF) (CSE: PHRX) Tilray, Inc. (NASDAQ:TLRY) and Vinco...
Mar 29, 2022 10:40 am ET
Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
Mar 24, 2022 07:00 am ET
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
CAMBRIDGE, MA / ACCESSWIRE / March 24, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messengerRNA (mRNA) therapeutics and vaccines, today announced clinical and program updates demonstrating expansion and advancement of its mRNA pipeline. This announcement reflects the Company's commitment to expanding its portfolio by building on Moderna's experience with Spikevax®, its COVID-19 vaccine. The updates include advancements in the Company's respiratory and latent virus portfolios, updates on its global health programs, and new partnerships formed in
Mar 23, 2022 07:32 pm ET
Moderna Finalizes Strategic Partnership with Australian Government
On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually
Mar 23, 2022 08:00 am ET
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
CAMBRIDGE, MA / ACCESSWIRE / March 23, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age. This interim analysis showed a robust neutralizing antibody response in both age groups after a 25 µg two-dose primary series of mRNA-1273 along with a favorable safety profile. Based on these data, Moderna will submit a request f
Mar 22, 2022 10:00 am ET
UMass Chan Medical School announces research collaboration with Moderna to examine impact of Cytomegalovirus (CMV) in young children
Study will focus on group childcare and early childhood education settings located in Worcester and Cambridge to understand transmission and support prevention of CMV
Mar 22, 2022 07:20 am ET
Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day
mRNA-1230 is a combination respiratory vaccine candidate against SARS-CoV-2 virus, influenza virus and respiratory syncytial virus (RSV)
Mar 21, 2022 02:00 am ET
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine
CAMBRIDGE, MA / ACCESSWIRE / March 21, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with the Swiss Federal Government for seven million doses of Moderna's COVID-19 booster vaccine for anticipated delivery in 2023 an
Mar 18, 2022 09:31 am ET
Thinking about trading options or stock in Tesla, Docusign, Moderna, Dollar General, or American Express?
NEW YORK, March 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, DOCU, MRNA, DG, and AXP.
Mar 17, 2022 09:15 pm ET
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
CAMBRIDGE, MA / ACCESSWIRE / March 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has submitted a request to the U.S. Food and Drug Administration (FDA) for an amendment to the emergency use authorization (EUA) to allow for a fourth dose of its COVID-19 vaccine (mRNA-1273) in adults 18 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines. The request to include adults over 18 years of age was made to provide flexibili
Mar 17, 2022 11:00 am ET
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged 6-11 years.
Mar 16, 2022 08:00 am ET
Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine
CAMBRIDGE, MA / ACCESSWIRE / March 16, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the Ministry of Health, Labour and Welfare of Japan (MHLW) to supply Japan with an additional 70 million doses of Moderna's COVID-19 boo
Mar 15, 2022 09:31 am ET
Thinking about trading options or stock in Johnson & Johnson, GameStop, Delta Air Lines, Moderna, or Zoom Video?
NEW YORK, March 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JNJ, GME, DAL, MRNA, and ZM.
Mar 14, 2022 09:31 am ET
Thinking about trading options or stock in AstraZeneca, Anheuser Busch, Moderna, Lockheed Martin, or Wells Fargo?
NEW YORK, March 14, 2022 /PRNewswire/ --  InvestorsObserver issues critical PriceWatch Alerts for AZN, BUD, MRNA, LMT, and WFC.
Mar 14, 2022 09:15 am ET
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in a clinical trial of an experimental human immunodeficiency virus (HIV) trimer mRNA vaccine (mRNA-1574).
Mar 10, 2022 08:23 am ET
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate
Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)
Mar 10, 2022 08:00 am ET
Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022
CAMBRIDGE, MA / ACCESSWIRE / March 10, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its virtual Vaccines Day for analysts and investors at 8:00 a.m. ET on Thursday, March 24.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.